Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drug brolucizumab tested in Real-World patients

NCT ID NCT04543331

Completed Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study observed 572 patients with neovascular age-related macular degeneration or diabetic macular edema who were already receiving brolucizumab injections. Researchers collected routine medical data to see how well the drug resolved fluid in the eye and improved vision in real-world settings. The study did not impose a strict treatment schedule, reflecting actual clinical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

brolucizumab (a drug injected into the eye to reduce fluid and improve vision)

What this could lead to

If successful, this study could show that brolucizumab works well in everyday clinical practice, potentially leading to better treatment schedules for patients with these eye conditions.

What could go wrong

This is an observational study, not a controlled trial, so results may be influenced by patient selection and real-world variability. It does not prove cause and effect.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic macular edema wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC MACULAR EDEMA (DME) NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)

Contacts and locations

Locations

  • Novartis Investigative Site

    Munich, Bavaria, 81377, Germany

  • Novartis Investigative Site

    Würzburg, Bavaria, 97070, Germany

  • Novartis Investigative Site

    Würzburg, Bavaria, 97080, Germany

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, 60590, Germany

  • Novartis Investigative Site

    Göttingen, Lower Saxony, 37075, Germany

  • Novartis Investigative Site

    Osnabrück, Lower Saxony, 49076, Germany

  • Novartis Investigative Site

    Rostock, Mecklenburg-Vorpommern, 18057, Germany

  • Novartis Investigative Site

    Trier, Rhineland-Palatinate, 54296, Germany

  • Novartis Investigative Site

    Dresden, Saxony, 01307, Germany

  • Novartis Investigative Site

    Leipzig, Saxony, 04103, Germany

  • Novartis Investigative Site

    Schneeberg, Saxony, 08289, Germany

  • Novartis Investigative Site

    Halle, Saxony-Anhalt, 06118, Germany

  • Novartis Investigative Site

    Jena, Thuringia, 07740, Germany

  • Novartis Investigative Site

    Aschersleben, 06449, Germany

  • Novartis Investigative Site

    Bayreuth, 95445, Germany

  • Novartis Investigative Site

    Berlin, 10713, Germany

  • Novartis Investigative Site

    Berlin, 14163, Germany

  • Novartis Investigative Site

    Bonn, 53105, Germany

  • Novartis Investigative Site

    Breisach, 79206, Germany

  • Novartis Investigative Site

    Chemnitz, 09113, Germany

  • Novartis Investigative Site

    Cologne, 50968, Germany

  • Novartis Investigative Site

    Dresden, 01067, Germany

  • Novartis Investigative Site

    Dresden, 01324, Germany

  • Novartis Investigative Site

    Esslingen am Neckar, 73728, Germany

  • Novartis Investigative Site

    Glauchau, 08371, Germany

  • Novartis Investigative Site

    Homburg, 66421, Germany

  • Novartis Investigative Site

    Hösbach, 63768, Germany

  • Novartis Investigative Site

    Kiel, 24103, Germany

  • Novartis Investigative Site

    Leipzig, 04106, Germany

  • Novartis Investigative Site

    Magdeburg, 39104, Germany

  • Novartis Investigative Site

    Marienberg, 09496, Germany

  • Novartis Investigative Site

    Münster, 48145, Germany

  • Novartis Investigative Site

    Neubrandenburg, 17036, Germany

  • Novartis Investigative Site

    Neuburg am Inn, 86633, Germany

  • Novartis Investigative Site

    Saarbrücken, 66111, Germany

  • Novartis Investigative Site

    Schönebeck, 39218, Germany

  • Novartis Investigative Site

    Stralsund, 18435, Germany

  • Novartis Investigative Site

    Sulzbach, 66280, Germany

  • Novartis Investigative Site

    Torgau, 04860, Germany

  • Novartis Investigative Site

    Waren, 17192, Germany

  • Novartis Investigative Site

    Würzburg, 97080, Germany